Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €54.19 EUR
Change Today +1.33 / 2.52%
Volume 0.0
IL3 On Other Exchanges
As of 5:26 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

integra lifesciences holding (IL3) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/15 - €60.80
52 Week Low
10/17/14 - €33.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

integra lifesciences holding (IL3) Related Businessweek News

No Related Businessweek News Found

integra lifesciences holding (IL3) Details

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. In addition, it provides extremity products, including bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome, as well as regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. Further, the company offers instruments products, such as specialty and general surgical and dental instruments; and surgical lighting for hospitals, outpatient surgery centers, and physician, veterinarian, and dental practices. Integra LifeSciences Holdings Corporation sells its products directly through various sales forces and other distribution channels in the United States and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

3,400 Employees
Last Reported Date: 02/27/15
Founded in 1989

integra lifesciences holding (IL3) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $827.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $537.3K
Corporate Vice President of Global Operations...
Total Annual Compensation: $363.0K
Corporate Vice President and President of Spe...
Total Annual Compensation: $344.7K
Corporate Vice President of Administration, G...
Total Annual Compensation: $364.2K
Compensation as of Fiscal Year 2014.

integra lifesciences holding (IL3) Key Developments

Integra LifeSciences Announces Expansion of Credit Facility to $1.1 Billion

Integra LifeSciences Holdings Corporation announced that it has increased its credit facility with its bank group led by Bank of America, N.A. The expanded credit facility includes the following terms: An increase in the credit facility from $900 million to $1.1 billion, consisting of a $750 million revolver and term loans of $350 million; An option to increase the aggregate size of the facility by $200 million with additional commitments; No change in pricing terms or commitment fees to the existing facility; and no change to the current credit facility's maturity date of July 2, 2019. Integra LifeSciences plans to use the incremental term loan to refinance a portion of its revolving borrowings under its existing facility and to pay fees, costs and expenses incurred in connection with the expanded credit facility. The existing credit facility remains available for permitted acquisitions, to refinance certain indebtedness, to provide for working capital and for other general corporate purposes. Integra LifeSciences does not expect this increase in credit facility to have a material impact on 2015 financial performance.

Integra LifeSciences Holdings Corporation Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 04:50 PM

Integra LifeSciences Holdings Corporation Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 04:50 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Peter J. Arduini, Chief Executive Officer, President, Director and Member of Special Award Committee.

Integra LifeSciences Holdings Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Year to Date Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of 2015

Integra LifeSciences Holdings Corporation reported unaudited consolidated earnings results for the second quarter and year to date ended June 30, 2015. For the quarter, the company reported total revenues of $244,078,000 against $231,351,000 a year ago. Operating income was $13,954,000 against $12,392,000 a year ago. Income before income taxes was $7,572,000 against $7,186,000 a year ago. Net income was $4,998,000 or $0.15 per diluted share against $4,825,000 or $0.15 per diluted share a year ago. GAAP Net cash provided by operating activities was $18,126,000 against $16,377,000 a year ago. Adjusted net income was $26,300,000 or $0.79 per diluted share against $22,200,000 or $0.68 per diluted share a year ago. Adjusted EBITDA for the second quarter of 2015 was $50.5 million, or 20.7% of revenue, compared to $43.4 million, or 18.8% of revenue, in the prior year second quarter. Purchases of property and equipment were $13,112,000 against $9,356,000 a year ago. Free cash flow was $5,014,000 against $7,021,000 a year ago. GAAP net income was $4,998,000 compared with $4,825,000 a year ago. For the year to date, the company reported GAAP net cash provided by operating activities was $101,578,000 compared with $70,315,000 a year ago. Purchases of property and equipment were $43,244,000 compared with $44,067,000 a year ago. Free Cash Flow was $58,334,000 compared with $26,068,000 a year ago. Adjusted net income was $108,068,000 compared with $84,782,000 a year ago. The company provided earnings guidance for the full year 2015. The company now expects revenue of $870 million to $885 million, reported EPS of $1.12 to $1.22, and adjusted EPS of $3.00 to $3.10. The new guidance range for 2015 continuing operations is consistent with prior expectations. This new guidance reflects the removal of spine business for the full year, which is expected to have a $0.20 dilutive impact to adjusted EPS, and the slight accretion company expect from the TEI acquisition, net of any financing impact company expect to incur in the second half of 2015. The company is maintaining expectations for the underlying business excluding these transactions. Organic growth on a full year basis is now expected to be around 6%, about 1 point higher than previous guidance. Overall, top line growth, excluding currency, is now expected to be between 12% and 14% on a continuing operations basis. For the third quarter of 2015, the company is expecting revenues to be in a range of $222 million to $228 million, which reflects roughly flat sequential growth from base businesses, plus the incremental contribution from the TEI acquisition in the quarter. Organic growth on a year-over-year basis is expected to be in between a range of 4% to 6% in the third quarter. Looking at the third quarter, it expects adjusted earnings per share of $0.72 to $0.76, roughly flat to the second quarter' of $0.74 per share from continuing operations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IL3:GR €54.19 EUR +1.33

IL3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $130.85 USD -0.53
Globus Medical Inc $21.39 USD +0.50
Masimo Corp $39.26 USD +0.19
NuVasive Inc $50.54 USD +1.66
Wright Medical Group NV $20.67 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation IL3 Industry Range
Price/Earnings 50.5x
Price/Sales 2.1x
Price/Book 2.8x
Price/Cash Flow 42.0x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRA LIFESCIENCES HOLDING, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at